Gucy2g Inhibitors
Gucy2g inhibitors belong to a specific class of chemical compounds designed for the purpose of modulating the activity of the Guanylate cyclase 2G (Gucy2g) enzyme. Guanylate cyclases are a family of enzymes crucial to cellular signal transduction and various physiological processes. These enzymes catalyze the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), serving as essential secondary messengers in a wide range of cellular pathways. Gucy2g, as a member of this enzyme family, is expressed in specific tissues and cells within the human body. The primary goal of Gucy2g inhibitors is to interact with the Gucy2g enzyme in a selective manner, potentially influencing its catalytic activity and, consequently, impacting downstream cellular events mediated by cGMP.
Gucy2g inhibitors typically consist of small molecules or chemical compounds specifically designed to bind to Gucy2g, targeting either its active site or allosteric sites. This interaction can lead to the modulation of Gucy2g's behavior, potentially affecting its ability to convert GTP into cGMP. Researchers are primarily dedicated to unraveling the physiological roles and signaling pathways associated with Gucy2g and how inhibiting its activity with these compounds may provide insights into various cellular processes. The development of Gucy2g inhibitors represents an ongoing area of research within the field of molecular pharmacology and biochemistry, contributing to our understanding of cellular signaling mechanisms and the functions of guanylate cyclases in cellular physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone, an aldosterone antagonist, may indirectly affect transcriptional processes modulating Gucy2g expression through hormonal pathways that involve mineralocorticoid receptors. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to DNA, particularly at GC-rich sequences, interfering with transcription factor binding and potentially downregulating genes like Gucy2g. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220 is a protein kinase C inhibitor that could alter signaling pathways and thereby modulate the expression of genes including Gucy2g. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin (3'-deoxyadenosine) disrupts RNA synthesis leading to premature termination of mRNA chain elongation, which could diminish Gucy2g mRNA synthesis and its protein expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDAC). By altering chromatin structure, it could affect the transcription of certain genes, which might include Gucy2g. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine can non-selectively inhibit phosphodiesterases, which may lead to altered cyclic nucleotide levels and could have downstream effects on the expression of genes related to signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase inhibitor, which might modulate multiple signaling pathways and potentially affect Gucy2g expression as part of broad transcriptional changes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the MEK/ERK pathway, which is involved in cell signaling. Inhibition by PD98059 could lead to changes in gene expression, potentially reducing Gucy2g levels. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor which may modify inflammatory signaling pathways and influence the expression of various genes, possibly including Gucy2g. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has multiple cellular targets and has been shown to affect gene expression. Its broad modulatory effects could extend to Gucy2g transcription. | ||||||